Adalimumab Patent Expiration
Adalimumab Large Molecule Patents
Given below is the list of large molecule patents protecting Adalimumab, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Humira | USUS9683033 | Cell culture methods to reduce acidic species | Apr 26, 2032 | Abbvie Inc. |
| Humira | USUS9090688 | Methods for controlling the galactosylation profile of recombinantly-expressed proteins | Apr 26, 2032 | Abbvie Inc. |
| Humira | USUS9234032 | Fed-batch methods for producing adalimumab | Sep 13, 2027 | Abbvie Inc. |
| Humira | USUS9181337 | Modulated lysine variant species compositions and methods for producing and using the same | Mar 14, 2033 | Abbvie Inc. |
| Humira | USUS9334319 | Low acidic species compositions | Mar 14, 2033 | Abbvie Inc. |
| Humira | USUS8992926 | Methods of administering anti-TNFα antibodies |
Jun 05, 2022
(Expired) | Abbvie Inc. |
| Humira | USUS8420081 | Antibody formulations and methods of making same | Jan 13, 2030 | Abbvie Inc. |
| Humira | USUS9181572 | Methods to modulate lysine variant distribution | Mar 14, 2033 | Abbvie Inc. |
| Humira | USUS8883156 | Purified antibody composition | Apr 04, 2027 | Abbvie Inc. |
| Humira | USUS9090867 | Fed-batch method of making anti-TNF-alpha antibody | Sep 13, 2027 | Abbvie Inc. |
| Humira | USUS9090689 | Use of TNFα inhibitor for treatment of psoriasis |
Jul 18, 2023
(Expired) | Abbvie Inc. |
| Humira | USUS9315574 | Low acidic species compositions and methods for producing and using the same | Apr 21, 2033 | Abbvie Inc. |
| Humira | USUS9546212 | Methods of administering anti-TNFα antibodies |
Jun 05, 2022
(Expired) | Abbvie Inc. |
| Humira | USUS8906372 | Purified antibody composition | Apr 04, 2027 | Abbvie Inc. |
| Humira | USUS9266949 | Low acidic species compositions and methods for producing and using the same | May 13, 2033 | Abbvie Inc. |
| Humira | USUS9339610 | Removal of needle shield from syringes and automatic injection devices | Jan 24, 2032 | Abbvie Inc. |
| Humira | USUS9957318 | Protein purification methods to reduce acidic species | Apr 26, 2032 | Abbvie Inc. |
| Humira | USUS9913902 | Purified antibody composition | Apr 04, 2027 | Abbvie Inc. |
| Humira | USUS9150645 | Cell culture methods to reduce acidic species | May 13, 2033 | Abbvie Inc. |
| Humira | USUS8889136 | Multiple-variable dose regimen for treating TNFα-related disorders | Oct 09, 2027 | Abbvie Inc. |
| Humira | USUS9284370 | Methods for treating juvenile idiopathic arthritis | Jun 10, 2028 | Abbvie Inc. |
| Humira | USUS9512216 | Use of TNFα inhibitor | Apr 11, 2025 | Abbvie Inc. |
| Humira | USUS11083792 | Purified antibody composition | Apr 04, 2027 | Abbvie Inc. |
| Humira | USUS9187559 | Multiple-variable dose regimen for treating idiopathic inflammatory bowel disease | Apr 11, 2025 | Abbvie Inc. |
| Humira | USUS9499614 | Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosaccharides | Mar 14, 2034 | Abbvie Inc. |
| Humira | USUS8911964 | Fed-batch method of making human anti-TNF-alpha antibody | Sep 13, 2027 | Abbvie Inc. |
| Humira | USUS8999337 | Methods for treating juvenile idiopathic arthritis by inhibition of TNFα | Feb 06, 2031 | Abbvie Inc. |
| Humira | USUS8906373 | Use of TNF-alpha inhibitor for treatment of psoriasis |
Jul 18, 2023
(Expired) | Abbvie Inc. |
| Humira | USUS8916153 | Purified antibody composition | Apr 04, 2027 | Abbvie Inc. |
| Humira | USUS8911737 | Methods of administering anti-TNFα antibodies |
Jun 05, 2022
(Expired) | Abbvie Inc. |
| Humira | USUS9624295 | Uses and compositions for treatment of psoriatic arthritis | Mar 31, 2031 | Abbvie Inc. |
| Humira | USUS8986693 | Use of TNFα inhibitor for treatment of psoriasis | Apr 11, 2025 | Abbvie Inc. |
| Humira | USUS8961973 | Multiple-variable dose regimen for treating TNFα-related disorders | Apr 11, 2025 | Abbvie Inc. |
| Humira | USUS9522953 | Low acidic species compositions and methods for producing and using the same | Apr 26, 2032 | Abbvie Inc. |
| Humira | USUS8708968 | Removal of needle shields from syringes and automatic injection devices | Jan 24, 2032 | Abbvie Inc. |
| Humira | USUS8895009 | Purified antibody composition | Apr 04, 2027 | Abbvie Inc. |
| Humira | USUS9096666 | Purified antibody composition | Apr 04, 2027 | Abbvie Inc. |
| Humira | USUS9062106 | Methods for controlling the galactosylation profile of recombinantly-expressed proteins | Apr 26, 2032 | Abbvie Inc. |
| Humira | USUS9067992 | Use of TNFα inhibitor for treatment of psoriatic arthritis |
Jul 18, 2023
(Expired) | Abbvie Inc. |
| Humira | USUS11191834 | Protein formulations and methods of making same | Nov 28, 2028 | Abbvie Inc. |
| Humira | USUS9499616 | Modulated lysine variant species compositions and methods for producing and using the same | Mar 14, 2033 | Abbvie Inc. |
| Humira | USUS9669093 | Methods for treating juvenile idiopathic arthritis | Jun 10, 2028 | Abbvie Inc. |
| Humira | USUS9102723 | Purified antibody composition | Apr 04, 2027 | Abbvie Inc. |
| Humira | USUS9505834 | Methods for controlling the galactosylation profile of recombinantly-expressed proteins | Apr 26, 2032 | Abbvie Inc. |
| Humira | USUS8715664 | Use of human TNFα antibodies for treatment of erosive polyarthritis | Jul 24, 2027 | Abbvie Inc. |
| Humira | USUS9290568 | Methods to control protein heterogeneity | Mar 14, 2033 | Abbvie Inc. |
| Humira | USUS8974790 | Methods of administering anti-TNFα antibodies |
Jun 05, 2022
(Expired) | Abbvie Inc. |
| Humira | USUS9085619 | Anti-TNF antibody formulations | Nov 28, 2028 | Abbvie Inc. |
| Humira | USUS9085618 | Low acidic species compositions and methods for producing and using the same | Mar 14, 2033 | Abbvie Inc. |
| Humira | USUS8231876 | Purified antibody composition | Apr 04, 2027 | Abbvie Inc. |
| Humira | USUS6805686 | Autoinjector with extendable needle protector shroud |
May 06, 2023
(Expired) | Abbvie Inc. |
| Humira | USUS9284371 | Methods of producing adalimumab | Sep 13, 2027 | Abbvie Inc. |
| Humira | USUS8663945 | Methods of producing anti-TNF-alpha antibodies in mammalian cell culture | Sep 13, 2027 | Abbvie Inc. |
| Humira | USUS9346879 | Protein purification methods to reduce acidic species | Mar 14, 2033 | Abbvie Inc. |
| Humira | USUS8961974 | Multiple-variable dose regimen for treating TNFα-related disorders | Apr 11, 2025 | Abbvie Inc. |
| Humira | USUS9273132 | Purified antibody composition | Apr 04, 2027 | Abbvie Inc. |
| Humira | USUS9085620 | Use of TNFα inhibitor for treatment of psoriatic arthritis |
Jul 18, 2023
(Expired) | Abbvie Inc. |
| Humira | USUS8926975 | Method of treating ankylosing spondylitis | Jun 08, 2027 | Abbvie Inc. |
| Humira | USUS9359434 | Cell culture methods to reduce acidic species | Mar 14, 2033 | Abbvie Inc. |
| Humira | USUS9708400 | Methods to modulate lysine variant distribution | Mar 14, 2033 | Abbvie Inc. |
| Humira | USUS8906646 | Fed-batch method of making human anti-TNF-alpha antibody | Sep 13, 2027 | Abbvie Inc. |
| Humira | USUS9550826 | Glycoengineered binding protein compositions | Nov 14, 2034 | Abbvie Inc. |
| Humira | USUS8808700 | Use of TNF alpha inhibitor for treatment of erosive polyarthritis | May 16, 2026 | Abbvie Inc. |
| Humira | USUS11167030 | Protein formulations and methods of making same | Nov 28, 2028 | Abbvie Inc. |
| Humira | USUS9328165 | Purified antibody composition | Apr 04, 2027 | Abbvie Inc. |
| Humira | USUS9061005 | Multiple-variable dose regimen for treating idiopathic inflammatory bowel disease | Apr 11, 2025 | Abbvie Inc. |
Adalimumab's Family Patents
Explore Our Curated Drug Screens
Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List